Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and
tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at
least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were
treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the
anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS
were 1.4 months and 6.3 months.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Collaborators:
Tang-Du Hospital Yan'an University Affiliated Hospital